Microbiology and Biotechnology Letters (한국미생물·생명공학회지)

The Korean Society for Microbiology and Biotechnology (한국미생물·생명공학회)
권호 표지

Antimicrobial Effect of Novel Pyrrolidinyl-thio Carbapenem, CW-270031

신합성 카바페넴계 항생물질 CW-270031의 약효평가

  • Kim, Jong-Myeung (Department of Microbiology, Kyungpook National University) ;
  • Oh, Se-Woong (Central Research Institute, ChoongWae Pharma Corp.) ;
  • Ha, Jong-Ryul (Central Research Institute, ChoongWae Pharma Corp.) ;
  • Kim, Hong-Gi (Central Research Institute, ChoongWae Pharma Corp.) ;
  • Lee, Jin-Man (Department of Herb & Food Science, Kyungpook College of Science) ;
  • Lee, Sang-Han (Division of Life & Food Sciences, Kyungpook National University) ;
  • Kim, Byoung-Oh (Department of Applied Biology Sangju National University) ;
  • Kim, Jong-Guk (Department of Microbiology, Kyungpook National University)
  • 김종명 (경북대학교 미생물학과) ;
  • 오세웅 ((주)중외제약 종합연구소) ;
  • 하종렬 ((주)중외제약 종합연구소) ;
  • 김홍기 ((주)중외제약 종합연구소) ;
  • 이진만 (경북과학대학/바이오 건강산업연구소) ;
  • 이상한 (경북대학교 생명식품공학부) ;
  • 김병오 (상주대학교 생물응용학과) ;
  • 김종국 (경북대학교 미생물학과)
  • Published : 2006.12.28
Download PDF
⟨ Previous Next ⟩

Abstract

CW-270031, an injectable carbapenem, is a novel synthesized pyrrolidinyl-thio carbapenems. It was evaluated for its in vitro antibacterial activities in comparison with those of imipenem and meropenem against standard strains and clinical isolated strains, CW-270031 was more active than imipenem against gram-negative (E. coli and Klebsiella oxytoca) clinical isolates, but it was slightly active than meropenem. Against Klebsiella aeruginosa CW-118 MIC were 0.048 $\mu$g/ml for CW-270031, 0.19 $\mu$g/ml for imipenem. Against clinical E. coli MIC range were 0.012$\sim$0.195 $\mu$g/ml for CW-270031, 0.097$\sim$0.39 $\mu$g/ml for imipenem. Against clinical Klebsiella oxytoca MIC$_{50}$ were 0.09 $\mu$g/ml for CW-270031, 0.39 $\mu$g/ml for imipenem. Against gram-positive standard strains and clinical CW-270031 was slightly more activity than meropenem, but CW-270033 was less active than imipenem against these tested isolates. The subcutaneous injection of CW-270031 in mice revealed that the half-life of CW-270031 in serum was about 13 min, long than that of meropenem (10.6 min). CW-270031. was stable to hydrolysis by dog renal dehydropeptidase I (DHP-l) enzyme, to an more stabilities shown by meropenem.

Keywords

References

  1. Hackbarth, C. J. and H. F. Chambers. 1989. Methicillin-resistant staphylococci: genetics and mechanisms of resistance. Antimicrob. Agents Chemother. 33: 991-994
  2. Helmut, K., G. S. Jon, H. Richard, and Frederick, M. K. 1982. Metabolism of thienamycin and related carbapenem antibiotics by the renal dipeptidase, dehydropeptidase-I. Antimicrob. Agents Chemother. 22: 62-68
  3. Jones, R., A. Barry, and C. Thornsberry. 1989. In-vitro studies of meropenem. J. Antimicrob. Chemother. 24: 9-29 https://doi.org/10.1093/jac/24.1.9
  4. Kahan, J. S., F. M. Kahan, R. Goegelman, S. A. Currie, M. Jackson, E. O. Stapley, T. W. Miller, D. Hendlin, S. Mochales, S. Hernandez, and H. B. Woodruff. 1976. 16th Intersci. Conf. Antimicrob. Agents Chemother., Abst. p227, The American Society for Microbiology, Washington, D.C., USA
  5. Kahan, J. S., F. M. Kahan, R. Goegelman, S. A. Currie, M. Jackson, E. O. Stapley, T. W. Miller, A. K. Miller, D. Hendlin, S. Mochales, S. Hernandez, H. B. Woodruff, and J. Birnbaum, 1979. Thienamycin, a new beta-lactam antibiotic. I. Discovery, taxonomy, isolation and physical properties. J. Antibiot., 32: 1-12
  6. Kropp, H., J. S. Kahan, F. M. Kahan, J. Sandorf, G. Darland, and J. Birnbaum. 1976. 16th Intersci. Conf. Antimicrob. Agents Chemother., 1976, Abst. 228, The American Society for Microbiology, Washington, D.C., USA
  7. Moellering, R., G. Eliopoulos, and D. Sentochnik. 1989. The carbapenems: new broad spectrum ${\beta}$-lactam antibiotics. J. Antimicrob. Chemother. 24: 1-7 https://doi.org/10.1093/jac/24.1.1
  8. National Committee for Clinical Laboratory Standards. 1997. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, Vol. 17. Approved standard M7-A4. National Committe for Clinical Laboratory Standards, Wayne, Pa
  9. Petersen, P., N. Jacobus, W. Weiss, and R. Testa. 1991. In vitro and in vivo activities of LJC 10,627, a new carbapenem with stability to dehydropeptidase I. Antimicrob. Agents Chemother. 35: 203-207
  10. Pitkin, D., W. Sheikh, and H. Nadler. 1997. Comparative in vitro activity of meropenem versus other extended-spectrum antimicrobials against randomly chosen and selected resistant clinical isolates tested in 26 North American Centers. Clin. Infect. Dis. 24: S238-S248
  11. Asahi, Y., M. Shuichi, and Y. Keizo. 1995. In vitro and in vivo antibacterial activities of Bo-2727, a new carbapenem. Antimicrob. Agents Chemother. 39: 1030-1037
  12. 의약품 등의 독성시험기준(식품의약품안전청 고시 제 1999-61호)